Ibrutinib has been selected for Medicare price negotiation under the Inflation Reduction Act. The authors summarize the House Oversight Committee investigation to be considered by CMS during the price ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback